A B S T R A C T It has been postulated that lipoprotein lipase, an enzyme important in the uptake of fatty acids into tissues, is bound to the vascular endothelial cell surface and that this binding occurs through attachment to heparinlike glycosaminoglycans. Furthermore, it is thought that heparin releases the enzyme from its attachment to the endothelium into the circulation. These hypotheses have never been tested directly in cell systems in vitro. In the present study we have directly evaluated the interaction of lipoprotein lipase, purified from bovine skim milk with monolayer cultures of endothelial cells, isolated from bovine pulmonary artery.
not associated with a release of [3S]glycosaminoglycans from 35S-prelabeled cells.
Reductions of lipoprotein lipase binding to endothelial cells and of cell surface-associated [35S]glycosaminoglycans in 35S-prelabeled cells occurred in parallel both when cells were pretreated with crude Flavobacterium heparinum enzyme before lipoprotein lipase binding and when cells were treated with this enzyme after lipoprotein lipase binding. The removal of heparan sulfate from the cell surface by purified heparinase totally inhibited the binding of lipoprotein lipase by endothelial cells, but the removal ofchondroitin sulfate by chondroitin ABC lyase had no effect on this binding.
These results provide direct evidence for lipoprotein lipase attachment to endothelial cells through heparan sulfate on the cell surface, and provide evidence for the release of lipoprotein lipase by heparin through a detachment from this binding site. INTRODUCTION Triglycerides, transported in plasma by chylomicrons and very low density lipoproteins, are hydrolyzed by lipoprotein lipase (glycerol ester hydrolase) (EC 3.1.1.3). This hydrolysis is thought to take place at the vascular surface, thereby making fatty acids available for uptake by the tissues (1, 2) . Lipoprotein lipase activity is readily released into the circulating blood by heparin injection (3) , and the interaction between lipoprotein lipase and heparin in vitro has been well studied. Lipoprotein lipase binds to heparin immobilized to agarose gel, and this binding can be dissociated by addition of sodium chloride at high concentration, which suggests that the binding occurs mainly through electrostatic interaction (4, 5) . Under certain conditions, heparin increases the enzymatic activity and the stability of crude lipoprotein lipase preparations (3, 6) , but has no effect on the enzymatic activity of purified lipoprotein lipase (6) . Recent studies have demonstrated that lipoprotein lipase also binds to other glycosaminoglycans such as heparan sulfate (a glycosaminoglycan structural'ly related' to heparin), dermatan sulfate, and, to a lesser extent, chondroitin sulfate, although the interaction of lipoprotein lipase with these glycosaminoglycans is weaker than with heparin (7) .
Glycosaminoglycans such as heparan sulfate have been reported to be surface components of many mammalian cells in culture (8) , including endothelial cells (9) (10) (11) . Thus, it has been postulated (12, 13) and dissolved in 2 ml of 50% glycerol, 15 mM potassium phosphate buffer (pH 6.8), or, in some cases, in 2 ml of Hanks' balanced salt solution containing 2% bovine serum albumin and stored at -20°C. The purified enzyme, with a specific activity of 400-650 ,umol of free fatty acid released/min per mg protein in the assay system described below, demonstrated one major band on sodium dodecylsulfate-polyacrylamide gel electrophoresis performed according to the method of Weber and Osborn (19) .
Assay for lipoprotein lipase. The assay for lipoprotein lipase activity was performed as previously described by Nilsson-Ehle and Schotz (20) , with an emulsion of Tri-[9,10-3H]oleoylglycerol as substrate. The radioactive substrate was added so that the specific activity was 800-900 cpm/ nmol of triglyceride throughout the experiments. The amount of enzyme assayed was selected so that no more than 7% ofthe substrate was hydrolyzed during the incubations. Under these conditions the hydrolysis of substrate was linear with time. 1 mU of enzymatic activity was defined as the release of 1 nmol of fatty acid/min at 37°C.
Binding of lipoprotein lipase to endothelial cells. For binding experiments, the purified lipoprotein lipase in glycerol was usually diluted 1,000-to 2,000-fold with RPMI 1640 culture media containing 10% bovine serum. For the study of saturation kinetics, the purified enzyme which had been dissolved in Hanks' balanced salt solution containing 2% bovine serum albumin was used for dilution. 1 ml of medium containing lipoprotein lipase was added to the endothelial monolayer cultures (35-mm petri dishes), which were then incubated for 40 min at room temperature. The culture media were collected and maintained at 40C before assay for unbound enzymatic activity of lipoprotein lipase. After the cell layer was rinsed twice with 2 ml of iced Hanks' balanced salt solution, 0.5 or 1 ml of this buffer was added and the cells were removed from the petri dishes by scraping with a rubber policeman. Two (Fig. 2) , which indicates saturation. In experiments carried out with different cell culture preparations, the mean maximal lipoprotein lipase activity bound to cells was 9,400± 1,900 mU/mg of cell protein, and the mean concentration of lipoprotein lipase at half-maximal binding (K.) was 20,200+1,300 mU/ml (mean±SE of four experiments). These values correspond to 0.24 nmol of lipoprotein lipase/mg of cell protein and a concentration of 0.52 uM, respectively, on the assumption of a dimeric molecular weight of 100,000, as described by Iverius et al. (18) .
Release of lipoprotein lipase by glycosaminoglycans. Fig. 3 demonstrates the release of lipoprotein lipase from cells by increasing concentrations of heparin. The incubation with Hanks' balanced salt solution alone released -10% of the bound lipoprotein lipase activity. Incubation with 0.6 ,ug/ml heparin resulted in the release of 90% of bound lipoprotein lipase activity and further increase of heparin concentration failed to cause additional lipoprotein lipase release from the cells. Furthermore, Fig. 3 shows that lipoprotein lipase activity released from the cells was quantitatively recovered in the heparin solution without loss or enhancement of lipoprotein lipase activity initially associated with cells.
The lipoprotein lipase releasing effect ofheparin was compared with that ofother glycosaminoglycans (Table  I ). Among the glycosaminoglyeans tested, heparin displaced the enzyme from cells at the lowest concentration (0.6 ,ug/ml). Heparan sulfate and dermatan sulfate required a higher concentration to displace the enzyme, and chondroitin sulfate failed to release the enzyme even at the highest concentration tested (30 ug/ml).
Treatment of endothelial cells with crude F. heparinum enzyme. Effects of cell treatment with crude F. heparinum enzyme are shown in Fig. 4 Crude F. heparinum Enzyme (U/ml) FIGURE 5 Release of cell-bound lipoprotein lipase by treatment of cells with crude F. heparinum enzyme. Endothelial cell cultures were incubated with 440+40 mU/ml of lipoprotein lipase (mean and range of two separate experiments) for 40 min at room temperature. Control cultures were determined for cell-bound lipoprotein lipase activity without further treatments (C). Other endothelial cell cultures were then incubated with 0.5 ml of Hanks' balanced salt solution containing crude F. heparinum enzyme (0, 0.3, and 2.5 U/ml) for 40 min at 37°C. Lipoprotein lipase activity released into the solution (m) and that remaining on cells (a) were determined as described in Methods. The data are expressed as the ratio of lipoprotein lipase activity to cell protein for each dish. The mean of two separate experiments is shown. In all cases, the observed range was <±9% of the mean value of two experiments.
the bound lipoprotein lipase to 21 and 9%, respectively, of that of untreated cells (Fig. 5) Identical enzymatic digestions were also performed with unlabeled endothelial cell cultures for the study of lipoprotein lipase binding to cells. (24) . Since the enzyme can be synthesized by other isolated cells such as adipocytes (25) and heart cells (26, 27) , it has been postulated that cells other than the endothelium are the source of lipoprotein lipase and that the enzyme is transferred to the endothelium, where it binds to the plasma membrane (2, 12, 13 (30) and Chinese hamster ovarian cells (31) on addition of heparin. Among various glycosaminoglycans, only heparin and heparan sulfate, but none ofthe other polysaccharides, were able to displace the endogenous polysaccharide (30) . Under (14) . Furthermore, the cells treated with F. heparinum enzyme do not show any degradation of cellular protein and are able to continde normal glycosaminoglycan synthesis (14) . Hence, it is very unlikely that the interference with binding by this treatment is due to proteinase activity in F. heparinum enzyme preparations.
To test the effect of the selective removal of these glycosaminoglycans, we used purified heparinase, which does not degrade chondroitin sulfate (33) and chondroitin ABC lyase, which does not degrade heparan sulfate (22) . The use of these enzymes showed that binding of lipoprotein lipase was almost completely inhibited when cells were treated with purified heparinase, but there was no influence on binding of lipoprotein lipase after the treatment of cells with chondroitin ABC lyase. Thus, this approach indicates that heparan sulfate is the glycosaminoglycan through which lipoprotein lipase attaches to the cell surface.
Lipoprotein lipase may serve as a prototype of other plasma components such as platelet factor 4, some clotting factors, antithrombin III, and lipoproteins that also have the capability to bind heparin and other polysaccharides (8) . It is possible that heparan sulfate on the endothelial cell surface plays a role in the interactions of the vascular surface with these components, as well as with lipoprotein lipase. Such an interaction has already been described for platelet factor 4 (34) .
